By definition, “quality control” means a process by which entities review the quality of all factors involved in production. For any entity involved in the production of pharmaceuticals and heathcare products, it encompasses a detailed system of inspection and control covering the production, evaluation, and distribution of every product bearing the Taj Oncology label or those of our clients. Taj Oncology's approach to quality control emphasizes three aspects:
- Elements such as controls, job management, defined and well managed processes, performance and integrity criteria, and the identification of records
- Competence such as knowledge, skills, experience, and qualifications
- Soft elements such as personnel integrity, confidence, company culture, motivation, teamwork, and quality working relationships.
Taj Oncology's quality control system emphasizes the rigorous testing of products to uncover defects, and reporting to management who make the decision to allow or deny the release, whereas quality assurance attempts to improve and stabilize production, and associated processes, to avoid issues that lead to defects. As quality control issues are among the top reasons for not renewing contracts in the pharmaceutical industry, Taj Oncology is proud to say we have never lost a customer due to quality issues.
Taj Pharma Group
A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj Pharma Group is spreading its footprint globally through excellence and innovation.
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the export market remains the priority. For others it is developing a robust presence in domestic markets given growing population of India. And then there are Group companies, a small but growing number, that have global ambitions; additionally, synchronizing these ventures to cater Indian market remains a priority for growth.
Exports from India remain the cornerstone of the Taj Pharma Group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in Spain, Germany, Middle East, Africa, Russia, and CIS Countries), joint ventures (in Sri Lanka, UK) and acquisitions.
While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are UK, Sri Lanka, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts to internationalize its operations thus: “We hope that a several years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today." We have already progressed on such efforts by our current presence in more than 40 countries.